World EPA Congress 2022
Attending World EPA Congress March 22-24 in Amsterdam? Don’t miss PRECISIONadvisors Richard Macaulay and David Carr present “Gene Therapies Market Access: Lessons From The Past, Future Best Practice” March 23 at 11:45 CET, and be sure to stop by our booth to speak with one of our experts.
Bringing Social Determinants of Health to Life to Optimize Health Outcomes in Patients With Chronic Conditions
As the United States and the world have seen firsthand how social determinants of health (SDOH) impact the mortality and morbidity of patients contracting the COVID-19 virus, addressing SDOH has become a national priority in health care. Organizations nationwide are increasingly looking to integrate SDOH and health equity into value-based strategies.
Within Innovative Oncology Space, Companies Need to Address Oncologists’ Needs
The oncology space is undergoing a tremendous amount of innovation, as novel new products and practices become available. But those treatments can do only so much good if oncologists aren’t using them. Precision’s Christy Banach and Janet Serluco weigh in on the opportunity biopharma companies have to differentiate themselves from their competitors by addressing oncologists’ specific needs.
Rethinking Diabetes Care in the Digital Age
In 2021, NCQA and HL7 hosted the fifth annual Digital Quality Summit (DQS) that convened stakeholders within six distinct “tracks” – each track exploring a different subset of healthcare. PRECISIONvalue’s Dominic Galante, MD, Jorge Font, MPH, and Maureen Hennessey, PhD, provided consultation to the Helmsley Charitable Trust, sponsors of the Track 6 “Rethinking Diabetes Care in the Digital Age.” Dr. Hennessey and Michael Barr, MD, of NCQA served as track co-leaders.
Conference: Gene Therapy for Rare Disorders, 2022
Precision will be at this year’s Gene Therapy for Rare Disorders from March 7 – 10th in Boston. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization of therapies for rare genetic disorders.
Pharma Industry Aims to Expand Its Role in Addressing Social Determinants of Health
From federal lawmakers to pharmaceutical companies, plans, providers and other health care stakeholders, efforts are coalescing to address social determinants of health (SDOH). Initiatives are ramping up in response to COVID-19’s disparate impact on vulnerable populations and communities across the U.S. and include pharma collaborations with payers and health systems focusing on social determinants relevant to medication adherence and access.
Podcast: How to be a great leader (at every level) with Carlos Delucca
We’re excited to announce our new podcast, Sound Advice. Greg Forte, Senior Director of Learning & Development, invites Precision Value & Health thought leaders to have candid conversations about leadership, professional development, and hot topics in the healthcare space.
On-Demand Webinar – Global Market Access: The Year Ahead
As we emerge from another surge in coronavirus cases, there is good reason to believe we are starting 2022 in a better position than we were this time last year. Yet uncertainty remains. COVID-19 will have a lasting effect on healthcare budgets, as well as in areas such as clinical trials, regulatory processes and reimbursement timelines. At the same time, we are at the cusp of another wave of innovation, with a raft of new treatment modalities due to launch in the coming 12 months.
Healthcare Agency Roundtable
In this edition of Med Ad News, executive management from healthcare communications agencies and networks participate in the special feature Healthcare Agency Roundtable. Precision’s Jackie DeAngelis, Andrew Cournoyer, and Isabella Sergio weigh in on topics ranging from the COVID-19 pandemic to diversity, equity and inclusion.
Self-Reported Health Care Resource Utilization in Clinical Trials
Real-world data are important sources within health care resource utilization (HCRU) research, but these databases often are repurposed for this use rather than custom designed. Some researchers are beginning to collect HCRU data within the context of clinical trials, with the intention to address research questions of interest, rather than relying solely on data salvaged from insurance claims or electronic health records.
